Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center.
Andrew S TsengJ William SchleiferWin-Kuang ShenRobert McBaneSunil MankadHeidi EsserDarko VucicevicFadi E ShamounPublished in: Clinical cardiology (2017)
Our findings are largely compatible with the results of LVSD or HF subgroups in RE-LY, ROCKET-AF, and ARISTOTLE trials and add to increasing confidence that DOACs can be safely used for stroke and systemic embolism prevention in patients with LVSD.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- left ventricular
- venous thromboembolism
- end stage renal disease
- heart failure
- ejection fraction
- chronic kidney disease
- blood pressure
- newly diagnosed
- primary care
- oxidative stress
- risk factors
- left atrial
- acute myocardial infarction
- aortic stenosis
- hypertrophic cardiomyopathy
- adipose tissue
- percutaneous coronary intervention
- skeletal muscle